https://www.selleckchem.com/pr....oducts/sb-415286.htm
Three independent runs in a 300-ml working volume confirmed the robustness of this process. CONCLUSION A streamlined and controllable platform for large quantity manufacturing of pure functional atrial, ventricular and nodal cardiomyocytes on MCs in conventional-type stirred tank bioreactors was established, which can be further scaled up and translated to a good manufacturing practice-compliant production process, to fulfill the quantity requirements of the cellular therapeutic industry.BACKGROUND Catheter ablation of non-reentrant,
Like
Comment
Share
